Avanos Medical (AVNS) Common Equity (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Common Equity data on file, last reported at $782.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 6.83% year-over-year to $782.1 million; the trailing twelve-month figure through Mar 2026 stood at $782.1 million (down 6.83% YoY), and the FY2025 full-year result was $778.2 million, down 53.64% from the prior year.
• Common Equity rose to $782.1 million in Q1 2026, from $778.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.7 billion in Q2 2025 to a low of -$98.5 million in Q2 2024.
• A 5-year average of $930.7 million and a median of $1.2 billion in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 203.51% in 2024 and jumped 1812.59% in 2025, its largest moves.
• Tracing AVNS's Common Equity over 5 years: stood at $1.3 billion in 2022, then retreated by 4.25% to $1.2 billion in 2023, then soared by 35.78% to $1.7 billion in 2024, then tumbled by 53.64% to $778.2 million in 2025, then rose by 0.5% to $782.1 million in 2026.
• Business Quant data shows AVNS's Common Equity at $782.1 million in Q1 2026, $778.2 million in Q4 2025, and $778.0 million in Q3 2025.